MAP2K7 and neoplasm: Given that DSF/Cu + sorafenib had a more potent anti-tumor effect than sorafenib alone, one hypothesis is that DSF/Cu functions synergistically with sorafenib by also inhibiting the MEK/ERK signaling pathway.